Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeTaysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic. The company carries a $1.79B market cap, placing it firmly in the small-cap category. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Market Cap
$1.79B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-11.85
EPS (TTM)
$-0.41
EPS (Fwd)
$-0.46
ROE
-47.1%
ROA
-23.8%
Cash
$455.4M
Total Debt
$56.7M
Free CF
-$81.0M
52W Change
72.3%
Annual Financials
Cash vs Debt
Where TSHA stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, TSHA finished 2.52% above its 150-day moving average ($5.55) and 5.18% above its 200-day moving average ($5.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TSHA overbought or oversold?
At the September 1, 2026 close, TSHA's RSI(14) was 29.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $455.4M in cash comfortably exceeding the $56.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$81.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -47.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.5M (2022) to $9.8M (2025), reflecting a 291% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Taysha Gene Therapies, Inc.'s trajectory.